September 7, 2016: Markets opened mixed Wednesday following largely unmemorable sessions overseas. European markets await a policy statement from the ECB due Thursday morning. The Beige Book’s release did move equities somewhat…
The August 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest has significantly decreased.
August 24, 2016: Markets opened lower Wednesday and only the Nasdaq Composite made even a brief visit to positive territory during the day’s trading session. Healthcare and materials stocks led the losers…
Medivation has been among the top future biotech mergers for quite some time. The problem is that we still have no idea which company will buy Medivation, nor do we know what…
Credit Suisse has run bullish and bearish scenarios for what the firm feels is a reasonable upside and downside for each of its large cap pharmaceutical stocks.
The July 29 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest was lower.
The short interest data for the July 29 settlement date are out and it almost feels like short sellers are getting a bit panicked about the market rally.
August 9, 2016: Markets opened higher again Tuesday following the lead of Asian and European exchanges. The productivity report cooled investors’ enthusiasm, though, and afternoon trading saw equities slipping below the break-even…
August 8, 2016: Markets opened higher Monday but turned south shortly after the opening bell and remained in the red for the rest of the day. The dollar gained strength this afternoon…
Credit Suisse sees the Bristol-Myers Squibb gap with Merck getting even worse, even though it still has robust I-O franchise estimates for Bristol-Myers.
August 5, 2016: Markets opened higher Friday following the report of 255,000 new U.S. jobs added in July. The financial and tech sectors led the gainers today, the former likely on improved…
Bristol-Myers Squibb shares took a nosedive early Friday's following an update in its late-stage Checkmate trial. But Bristol-Myer's failure was a big win for Merck.
Merck reported better-than-expected second-quarter 2016 results before markets opened Friday morning.
Paul Ausick The short interest data have been released for the July 15 settlement date. For the selected pharmaceutical stocks, short interest was mixed.
Overall, one-third of the Dow Jones Industrial Average is reporting this week, and this has the potential to sustain the run that the Dow has made since the Brexit vote.
